BioCentury
ARTICLE | Clinical News

Amplyx reports Phase I data for APX001 in fungal infections

November 30, 2017 11:25 PM UTC

In October, Amplyx Pharmaceuticals Inc. (San Diego, Calif.) reported data from two Phase I trials in 166 healthy volunteers showing that oral and IV APX001 were well tolerated at all doses tested. Additionally, the company said the compound exceeded the target exposures for efficacy against Candida and Aspergillus. The average plasma half-life was about 2.5 days, and the oral formulation had >90% bioavailability. Data were presented at the IDWeek meeting in San Diego...